Therapy of Myelodysplastic Syndrome (MDS) with azacitidine given in combination with etanercept: A phase II study

被引：0
|
作者：
Holsinger, Aaron L. [1 ,2 ]
Ramakrishnan, Aravind [1 ,2 ]
Storer, Barry [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Petersdorf, Stephen [1 ,2 ]
Deeig, H. Joachim [1 ,2 ]
Scott, Bart L. [1 ,2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1452
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)
    Borate, Uma M.
    Dvorak-Kornaus, Kaitlyn M.
    Zhao, Qiuhong
    Koenig, Kristin L.
    Eisfeld, Ann-Kathrin
    Madanat, Yazan F.
    BLOOD, 2023, 142
  • [2] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [3] A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Daver, Naval G.
    Jabbour, Elias J.
    Alvarado, Yesid
    DiNardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Bose, Prithviraj
    Pemmaraju, Naveen
    Naqvi, Kiran
    Cortes, Jorge E.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Colla, Simona
    Yang, Hui
    Rausch, Caitlin R.
    Gasior, Yvonne
    Bueso-Ramos, Carlos E.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [4] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    CANCER RESEARCH, 2024, 84 (07)
  • [5] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [6] A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
    Guerra, Veronica A.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Masarova, Lucia
    Pemmaraju, Naveen
    Jabbour, Elias
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Zhou, Lingsha
    Pierce, Sherry A.
    Borthakur, Gautam M.
    Wierda, William G.
    Ferrajoli, Alessandra
    Sasaki, Koji
    Takahashi, Koichi
    Naqvi, Kiran
    Alvarado, Yesid
    Ohanian, Maro N.
    Jain, Nitin
    Bose, Prithviraj
    Ravandi, Farhad
    Konopleva, Marina Y.
    Estrov, Zeev E.
    Verstovsek, Srdan
    Daver, Naval G.
    BLOOD, 2019, 134
  • [7] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [8] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [9] Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
    Guerra, Veronica A.
    Burger, Jan A.
    Borthakur, Gautam M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    DiNardo, Courtney D.
    BLOOD, 2019, 134
  • [10] A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Berdeja, Jesus G.
    Komrokji, Rami S.
    Essell, James
    Lyons, Roger M.
    Maris, Michael
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    BLOOD, 2015, 126 (23)
12345